NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NK
CUSIPN/A
Phone858-633-0300
Debt
Debt-to-Equity Ratio0.03
Current Ratio5.45
Quick Ratio5.45
Price-To-Earnings
Trailing P/E Ratio-2.67
Forward P/E Ratio-2.05
P/E GrowthN/A
Sales & Book Value
Annual Sales$50,000.00
Price / Sales4,879.34
Cash FlowN/A
Price / CashN/A
Book Value$2.75 per share
Price / Book1.12
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-96,420,000.00
Net Margins-357,603.41%
Return on Equity-49.47%
Return on Assets-42.79%
Miscellaneous
Employees139
Outstanding Shares79,210,000
Market Cap$249.51 million
Nantkwest (NASDAQ:NK) Frequently Asked Questions
What is Nantkwest's stock symbol?
Nantkwest trades on the NASDAQ under the ticker symbol "NK."
How were Nantkwest's earnings last quarter?
Nantkwest Inc (NASDAQ:NK) issued its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $0.10 million. Nantkwest had a negative return on equity of 49.47% and a negative net margin of 357,603.41%. View Nantkwest's Earnings History.
When is Nantkwest's next earnings date?
What price target have analysts set for NK?
2 brokerages have issued twelve-month target prices for Nantkwest's stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Nantkwest's share price to reach $3.00 in the next year. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for Nantkwest.
What is the consensus analysts' recommendation for Nantkwest?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nantkwest.
Who are some of Nantkwest's key competitors?
Some companies that are related to Nantkwest include Avrobio (AVRO), BAVARIAN NORDIC/S (BVNRY), Adaptimmune Therapeutics (ADAP), BioCryst Pharmaceuticals (BCRX), Heska (HSKA), CASI Pharmaceuticals (CASI), Fate Therapeutics (FATE), La Jolla Pharmaceutical (LJPC), Mesoblast (MESO), Voyager Therapeutics (VYGR), Vericel (VCEL), Novavax (NVAX), Replimune Group (REPL), Nightstar Therapeutics (NITE) and Translate Bio (TBIO).
Who are Nantkwest's key executives?
Nantkwest's management team includes the folowing people:
- Dr. Patrick Soon-Shiong FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 65)
- Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 53)
- Mr. Richard J. Tajak, Consultant (Age 65)
- Ms. Sonja Nelson, Chief Financial Officer (Age 45)
- Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 61)
When did Nantkwest IPO?
(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.
Has Nantkwest been receiving favorable news coverage?
News headlines about NK stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nantkwest earned a media and rumor sentiment score of 0.05 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.68 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Nantkwest.
Who are Nantkwest's major shareholders?
Nantkwest's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.22%), Renaissance Technologies LLC (0.66%), Dimensional Fund Advisors LP (0.27%), Millennium Management LLC (0.25%), Bank of New York Mellon Corp (0.22%) and Alps Advisors Inc. (0.11%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas and Steve Gorlin. View Institutional Ownership Trends for Nantkwest.
Which major investors are selling Nantkwest stock?
Which major investors are buying Nantkwest stock?
NK stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, Bank of New York Mellon Corp and Millennium Management LLC. View Insider Buying and Selling for Nantkwest.
How do I buy shares of Nantkwest?
Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nantkwest's stock price today?
One share of NK stock can currently be purchased for approximately $3.08.
How big of a company is Nantkwest?
Nantkwest has a market capitalization of $249.51 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Nantkwest employs 139 workers across the globe.
How can I contact Nantkwest?
Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]
MarketBeat Community Rating for Nantkwest (NASDAQ NK)
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
